Cannabis use and oral diseases

Evidence-Based Dentistry

Volumn 12, Issue 2, 2011, Pages 38-

  Veitz Keenan, Analia ^a,b   Spivakovsky, Silvia ^a,b  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b PEARL Network Practitioners   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959686315     PISSN: 14620049     EISSN: 14765446     Source Type: Journal    
DOI: 10.1038/sj.ebd.6400786     Document Type: Note

References (5)

1. Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids.Ther Clin Risk Manag 2010; 6: 59-63.
2. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 2010; 33:128-130.
3. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009; 6: 713-737.
4. Shapiro GK, Buckey-Hunter L. What every adolescent needs to know: cannabis can cause psychosis. J Psychosom Res 2010; 69: 533-539.
5. Warnakulasuriya S. Causes of oral cancer - an appraisal of controversies. Br Dent J 2009; 207: 471-475.